Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2017, Article ID 7593027, 12 pages
https://doi.org/10.1155/2017/7593027
Research Article

Components of Goutengsan in Rat Plasma by Microdialysis Sampling and Its Protection on Aβ1–42-Induced PC12 Cells Injury

1Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Shi Zi Street No. 100, Hongshan Road, Jiangsu, Nanjing 210028, China
2Key Laboratory of New Drug Delivery System of Chinese Materia Medica, Jiangsu Provincial Academy of Chinese Medicine, Shi Zi Street No. 100, Hongshan Road, Jiangsu, Nanjing 210028, China
3School of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, China
4School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China
5School of Traditional Chinese Medicine, China Pharmaceutical University, Nanjing 211198, China
6Jumpcan Pharmaceutical Co., Ltd., Taixing 225400, China

Correspondence should be addressed to Liang Feng; moc.361@ihsuixomnew

Received 1 December 2015; Revised 20 February 2016; Accepted 12 May 2016; Published 2 March 2017

Academic Editor: Helmut Hugel

Copyright © 2017 Hou-Cai Huang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Goutengsan, a Chinese herbal formula, potential protection on Alzheimer’s disease (AD) has been less reported. In current study, we investigated the protection of Goutengsan on Aβ1–42-induced pheochromocytoma-derived cells (PC12). Furthermore, the components from Goutengsan in rat plasma were identified by microdialysis (MD) for in vivo sampling. Meanwhile, the protection of components identified was also verified. At last, we found that Goutengsan has a potential protective effect on Aβ1–42-induced PC12 cells via reducing cells damage and increasing cells vitality as well as six components (pachymic acid, liquiritin, rhynchophylline, isorhynchophylline, corynoxeine, and isocorynoxeine) which may be effective components. This study helps to understand the treatment of Goutengsan for AD and would facilitate the clinical and further studies for this formula.